Syngene is up 20 percent this week, up 7 percent for the day, this year it is up 78 percent trading at a fresh 52-week high. The stock is trading at 45 times its FY22 EPS and the market cap now is now approximately Rs 20,000 crore.
This week, the company received Indian Council of Medical Research (ICMR) approval for HiMedia-Syngene's COVID-19 antibody test kit, ELISafe 19.
HiMedia Laboratories and Syngene International have collaborated to manufacture ELISafe 19TM, an IgG based ELISA test kit for COVID-19. The ELISafe 19TM antibody test kit has a sensitivity of 100 percent and specificity of 99 percent, the company said.
In CNBC-TV18’s special segment Stock 360 Anuj Singhal tells you all you need to know about Syngene.
To watch other videos in this series, click the Stock 360 tab below